The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. RESULTS: A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. CONCLUSIONS AND RELEVANCE: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medical uses of THC-based cannabinoids are associated with an increased risk of short-term adverse effects, but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, data analysis using SMD allowed the inclusion of a large variety of measurements in the evaluation of the outcomes and allowed us to include many more RCTs for all relevant medical indications than in a previous extensive meta-analysis [3].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that efforts to selfmanage depression with cannabis are increasing [71][72][73][74][75] (also Aaron L. Sarvet, MPH, written communication, January 2, 2018) despite lack of evidence that cannabinoids are effective for this purpose 76,77 ; prospectively, cannabis worsens the course of depressive disorders.78”
From Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [75]
In the citing paper
“Several clinical studies have demonstrated the analgesic effects of cannabinoids in human disease states, including pain associated with diabetes, chemotherapy, multiple sclerosis, and fibromyalgia (Lynch and Ware, 2015;Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“A comprehensive meta-analysis shows that medicinal cannabis and cannabinoids effectively alleviate different types of pain, such as neuropathic, fibromyalgia, multiple sclerosis, cancer, diabetic neuropathy, refractory pain due to multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal problems, and chemotherapy-induced pain (Whiting”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“Although several studies show that 'medical cannabis' can improve various types of pain, cannabimimetic side effects, which include drowsiness or fatigue, dizziness, dry mouth, nausea, and cognitive effects, have also been reported (Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,461
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Flagged first, then by citations
Research works printed but not linked: 20
- [8]8. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence /cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
- [14]14. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
- [16]16. Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. Paper presented at: IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
- [18]18. Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
- [46]46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50 (4):636-645.
- [48]48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
- [50]50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
- [52]52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
- [54]54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
- [56]56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
- [63]63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
- [80]80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- [90]90. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
- [116]116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org /ISRCTN15330757. Accessed April 7, 2014.
- [136]136. Zajicek J, Reif M, Schnelle M; UK MUSEC Study Investigators. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis -results of the MUSEC study. Paper presented at: IACM 5th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany. 137.
- [93]93. Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. Paper presented at: 22nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain. 138. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands. 139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014. 140. Institut fur Klinische Forschung Germany;
- [155]155. Rohleder C, Pahlisch F, Schaefer C, et al. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? Paper presented at: 8th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893 .2012.00392.x. · DOI
- [164]164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www .meddra.org/. Accessed September 2, 2014.
- [178]178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
- [179]179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
Cited by
Sorted by citations
Items 301–400 of 1,002
Lunn, S. E., Diaz, P. L., O’Hearn, S., Cahill, S. P., Blake, A., Narine, K. A. D., & Dyck, J. R. B. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0037 · Cited by 61
The neuropharmacology of cannabinoid receptor ligands in central signaling pathways
Brunt, T. M., & Bossong, M. G. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14982 · Cited by 67
Weiss, M. C., Hibbs, J. E., Buckley, M. E., Danese, S. R., Leitenberger, A., Bollmann‐Jenkins, M., Meske, S. W., Ruiz, K. A., McHugh, T. W., Larson, S. L., et al. (2021) · Cancer · doi:10.1002/cncr.33906 · Cited by 63
Tumati, S., Lanctôt, K. L., Wang, R., Li, A., Davis, A., & Herrmann, N. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00913-y · Cited by 65
Mastinu, A., Premoli, M., Ferrari‐Toninelli, G., Tambaro, S., Maccarinelli, G., Memo, M., & Bonini, S. A. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0013 · Cited by 62
Effects of cannabis tetrahydrocannabinol on endocannabinoid homeostasis in human placenta
Maia, J. C., Midão, L., Cunha, S. C., Almada, M., Fonseca, B. M., Braga, J. S., Gonçalves, D. R., Teixeira, N. A. A., & Correia‐da‐Silva, G. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02389-7 · Cited by 63
The Effect of Medical Marijuana Laws on Labor Market Outcomes
Sabia, J. J., & Nguyen, T. T. (2018) · The Journal of Law and Economics · doi:10.1086/701193 · Cited by 61
Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches
Bonn‐Miller, M. O., ElSohly, M. A., Loflin, M., Chandra, S., & Vandrey, R. G. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474730 · Cited by 61
Sainsbury, B., Bloxham, J., Pour, M. H., Padilla, M., & Enciso, R. (2021) · Journal of Dental Anesthesia and Pain Medicine · doi:10.17245/jdapm.2021.21.6.479 · Cited by 61
Choo, E. K., Ewing, S. W. F., & Lovejoy, T. I. (2016) · JAMA · doi:10.1001/jama.2016.13677 · Cited by 60
Turgeman, I., & Bar‐Sela, G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1561859 · Cited by 65
Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders
Krebs, M., Kébir, O., & Jay, T. M. (2019) · European Journal of Pain · doi:10.1002/ejp.1377 · Cited by 64
Gali, K., Winter, S. J., Ahuja, N. J., Frank, E., & Prochaska, J. J. (2021) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/s13011-021-00352-3 · Cited by 59
Campbell, C. T., Phillips, M. S., & Manasco, K. B. (2017) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-22.3.176 · Cited by 59
Use of marijuana exclusively for medical purposes
Wall, M. M., Liu, J., Hasin, D. S., Blanco, C., & Olfson, M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.11.009 · Cited by 62
Chiu, R. G., Patel, S., Siddiqui, N., Nunna, R. S., & Mehta, A. I. (2021) · Spine · doi:10.1097/brs.0000000000004035 · Cited by 58
Quality of Life and a Surveillant Endocannabinoid System
Reis, R. A. D. M., Isaac, A. R., Freitas, H. R., de Almeida, M. M., Schuck, P. F., Ferreira, G. C., Andrade‐da‐Costa, B. L. D. S., & Trevenzoli, I. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.747229 · Cited by 63
The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12050682 · Cited by 58
A review of the anesthetic implications of marijuana use
Alexander, J. C., & Joshi, G. P. (2019) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2019.1603034 · Cited by 58
Holleran, G. E., Scaldaferri, F., Gasbarrini, A., & Currò, D. (2019) · Phytotherapy Research · doi:10.1002/ptr.6517 · Cited by 58
Ladha, K. S., McLaren-Blades, A., Goel, A., Buys, M. J., Farquhar-Smith, P. W., Haroutounian, S., Kotteeswaran, Y., Kwofie, K., Foll, B. L., Lightfoot, N. J., et al. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.09.026 · Cited by 62
Cahill, S. P., Lunn, S. E., Diaz, P. L., & Page, J. E. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.626853 · Cited by 56
Evaluation of two different Cannabis sativa L. extracts as antioxidant and neuroprotective agents
Cásedas, G., Moliner, C., Maggi, F., Mazzara, E., & López, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1009868 · Cited by 56
Shetty, A., Delanerolle, G., Cavalini, H. F. S., Deng, C., Yang, X., Boyd, A. C., Fernandez, T., Phiri, P., Bhaskar, A., & Shi, J. Q. (2024) · Scientific Reports · doi:10.1038/s41598-023-49761-3 · Cited by 59
Citti, C., Battisti, U. M., Braghiroli, D., Ciccarella, G., Schmid, M. G., Vandelli, M. A., & Cannazza, G. (2017) · Phytochemical Analysis · doi:10.1002/pca.2722 · Cited by 58
Characteristics and Patterns of Marijuana Use in Community‐Dwelling Older Adults
Reynolds, I. R., Fixen, D. R., Parnes, B. L., Lum, H. D., Shanbhag, P., Church, S. D., Linnebur, S. A., & Orosz, G. M. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15507 · Cited by 57
Schleicher, E. M., Ott, F. W., Müller, M., Silcher, B., Sichler, M. E., Löw, M. J., Wagner, J. M., & Bouter, Y. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00094 · Cited by 58
Recent Advances in Understanding and Managing Tourette Syndrome
Thenganatt, M. A., & Jankovic, J. J. (2016) · F1000Research · doi:10.12688/f1000research.7424.1 · Cited by 56
Cannabis in Parkinson’s Disease: The Patients’ View
Yenilmez, F., Fründt, O., Hidding, U., & Buhmann, C. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202260 · Cited by 59
Cannabinoids and the kidney: effects in health and disease
Park, F., Potukuchi, P. K., Moradi, H., & Kovesdy, C. P. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00290.2017 · Cited by 58
Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases
Kienzl, M., Storr, M., & Schicho, R. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000120 · Cited by 57
Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature
Inglet, S., Winter, B., Yost, S. E., Entringer, S., Lian, A., Biksacky, M., Pitt, R. D., & Mortensen, W. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020930189 · Cited by 56
Cannabis Use in Patients With Cancer: A Clinical Review
Worster, B. K., Hajjar, E. R., & Handley, N. R. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00080 · Cited by 56
Cannabinoids for the treatment of dementia
Kuharić, D. B., Marković, D., Brković, T., Kegalj, M. J., Rubić, Ž., Vuica, A., Jerončić, A., & Puljak, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012820.pub2 · Cited by 55
Massuela, D. C., Hartung, J., Münz, S., Erpenbach, F., & Graeff-Hönninger, S. (2022) · Plants · doi:10.3390/plants11010140 · Cited by 55
Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation
Baratta, F., Pignata, I., Enri, L. R., & Brusa, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.888903 · Cited by 41
Scientific Advances in Thoracic Oncology 2016
Soo, R. A., Stone, E. C. A., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J. M., Mulshine, J. L., Yatabe, Y., Bubendorf, L., Đačić, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.019 · Cited by 55
Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids
Ngwa, W. F., Kumar, R., Moreau, M., Dabney, R., & Herman, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00208 · Cited by 55
Lapham, G. T., Matson, T. E., Carrell, D., Bobb, J. F., Luce, C., Oliver, M. M., Ghitza, U. E., Hsu, C. W., Browne, K. C., Binswanger, I. A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11677 · Cited by 54
Applications of Yeast Synthetic Biology Geared towards the Production of Biopharmaceuticals
Walker, R. S. K., & Pretorius, I. S. (2018) · Genes · doi:10.3390/genes9070340 · Cited by 54
Gong, X., Sun, C., Abame, M. A., Shi, W., Xie, Y., Xu, W., Zhu, F., Zhang, Y., Shen, J., & Aisa, H. A. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02880 · Cited by 54
Vázquez, M., Guevara, N., Maldonado, C., Guidó, P. C., & Schaiquevich, P. S. (2020) · BioMed Research International · doi:10.1155/2020/3902740 · Cited by 59
An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients
Erridge, S., Salazar, O., Kawka, M., Holvey, C., Coomber, R., Usmani, A., Sajad, M., Beri, S., Hoare, J. M., Khan, S. A., et al. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12183 · Cited by 54
Cannabis chemistry, post-harvest processing methods and secondary metabolite profiling: A review
Addo, P. W., Brousseau, V. D., Morello, V., MacPherson, S., Paris, M., & Lefsrud, M. G. (2021) · Industrial Crops and Products · doi:10.1016/j.indcrop.2021.113743 · Cited by 67
de Vries, M., Van Rijckevorsel, D. C. M., Vissers, K. C. P., Wilder‐Smith, O. H. G., & Van Goor, H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12811 · Cited by 54
Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials
Dykukha, I., Malessa, R., Essner, U., & Ueberall, M. A. (2021) · Pain Medicine · doi:10.1093/pm/pnab050 · Cited by 55
Cannabis for the treatment of Crohn's disease
Kafil, T. S., Nguyen, T. M., MacDonald, J. K., & Chande, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012853 · Cited by 53
Pichini, S., Mannocchi, G., Gottardi, M., Pérez-Acevedo, A. P., Poyatos, L., Papaseit, E., Pérez‐Mañá, C., Farré, M., Pacifici, R., & Busardò, F. P. (2019) · Talanta · doi:10.1016/j.talanta.2019.120537 · Cited by 53
Abdallah, F. W., Hussain, N., Weaver, T. E., & Brull, R. (2020) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2020-101340 · Cited by 57
Wong, S. S. C., Chan, W. S., & Cheung, C. W. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09905-y · Cited by 55
Wang, M. T. M., & Danesh-Meyer, H. V. (2020) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.07.002 · Cited by 53
Mohiuddin, M., Blyth, F., Degenhardt, L. J., Forti, M. D., Eccleston, C., Haroutounian, S., Moore, A., Rice, A. S. C., Wallace, M. S., Park, R., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000002000 · Cited by 53
Crowdfunding Cannabidiol (CBD) for Cancer: Hype and Misinformation on GoFundMe
Zenone, M. A., Snyder, J., & Caulfield, T. (2020) · American Journal of Public Health · doi:10.2105/ajph.2020.305768 · Cited by 52
Velayudhan, L., McGoohan, K., & Bhattacharyya, S. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003524 · Cited by 56
Down and High: Reflections Regarding Depression and Cannabis
Langlois, C. C., Potvin, S., Khullar, A., & Tourjman, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.625158 · Cited by 51
Cannabinoids, Insomnia, and Other Sleep Disorders
Lavender, I., McGregor, I. S., Suraev, A. S., Grunstein, R. R., & Hoyos, C. M. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.04.151 · Cited by 52
Perceptions of Safety of Daily Cannabis vs Tobacco Smoking and Secondhand Smoke Exposure, 2017-2021
Chambers, J., Keyhani, S., Ling, P. M., Hoggatt, K. J., Hasin, D. S., Nguyen, N. P. T., Woods, A., Ryder, A. L., & Cohen, B. E. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28691 · Cited by 56
Medical Marijuana Use in Older Adults
Briscoe, J., & Casarett, D. (2018) · Journal of The American Geriatrics Society · doi:10.1111/jgs.15346 · Cited by 52
Campbell, G., Stockings, E., & Nielsen, S. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0960-9 · Cited by 55
Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
Bahji, A., Meyyappan, A. C., & Hawken, E. R. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719892717 · Cited by 52
The nephrologistʼs guide to cannabis and cannabinoids
Rein, J. L. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000590 · Cited by 55
de Aguiar, A. C., Vardanega, R., Viganó, J., & Silva, E. K. (2023) · Molecules · doi:10.3390/molecules28093849 · Cited by 51
“[22], and National Academies of Sciences, Medicine, Health, Medicine, Board on Population, Public Health, Committee on the Health Effects of Marijuana: An Evidence and Research [2].”
BackgroundCannabis and cannabidiol (CBD) for the treatment of fibromyalgia
Berger, A. A., Keefe, J., Winnick, A. A., Gilbert, E., Eskander, J. P., Yazdi, C., Kaye, A. D., Viswanath, O., & Urits, I. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.08.010 · Cited by 57
Vinette, B., Côté, J., El-Akhras, A., Mrad, H., Chicoine, G., & Bilodeau, K. (2022) · BMC Cancer · doi:10.1186/s12885-022-09378-7 · Cited by 51
Differentiating Cannabis Products: Drugs, Food, and Supplements
Salehi, A., Puchalski, K., Shokoohinia, Y., Zolfaghari, B., & Asgary, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906038 · Cited by 53
Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease
Coles, M., Steiner-Lim, G. Z., & Karl, T. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.962922 · Cited by 57
HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads
Borgmann, K., & Ghorpade, A. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01143 · Cited by 51
Grammatikopoulou, M. G., Gkiouras, K., Theodoridis, X., Asteriou, E., Forbes, A., & Bogdanos, D. P. (2018) · Nutrients · doi:10.3390/nu10111737 · Cited by 51
Pain Management and Opioid Regulation: Continuing Public Health Challenges
Bonnie, R. J., Schumacher, M. A., Clark, J. D., & Kesselheim, A. S. (2018) · American Journal of Public Health · doi:10.2105/ajph.2018.304881 · Cited by 53
State marijuana laws and opioid overdose mortality
Chihuri, S. T., & Li, G. (2019) · Injury Epidemiology · doi:10.1186/s40621-019-0213-z · Cited by 52
Hossain, M. Z., Ando, H., Unno, S., & Kitagawa, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041423 · Cited by 54
Brown, J. D., Costales, B., van Boemmel-Wegmann, S., Goodin, A. J., Segal, R., & Winterstein, A. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041166 · Cited by 52
Colizzi, M., Ruggeri, M., & Bhattacharyya, S. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.00833 · Cited by 51
Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
Śledziński, P., Nowak, A., & Zeyland, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010263 · Cited by 53
Nutt, D., Phillips, L. D., Barnes, M. P., Brander, B., Curran, V. H., Fayaz, A., Finn, D. P., Horsted, T. I., Moltke, J., Sakal, C., et al. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0129 · Cited by 74
Voicu, V. A., Brehar, F.-M., Toader, C., Covache-Busuioc, R.-A., Corlatescu, A.-D., Bordeianu, A., Costin, H. P., Bratu, B.-G., Glavan, L.-A., & Ciurea, A. V. (2023) · Biomolecules · doi:10.3390/biom13091388 · Cited by 52
Hsu, G., Koçak, Ö., & Kovács, B. (2018) · Organization Science · doi:10.1287/orsc.2017.1167 · Cited by 50
Bruce, D., Brady, J. P., Foster, E., & Shattell, M. M. (2017) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2017.0184 · Cited by 50
Sohler, N., Starrels, J. L., Khalid, L., Bachhuber, M. A., Arnsten, J. H., Nahvi, S., Jost, J. T., & Cunningham, C. O. (2018) · Substance Use & Misuse · doi:10.1080/10826084.2017.1416408 · Cited by 50
Patient-Reported Symptom Relief Following Medical Cannabis Consumption
Stith, S. S., Vigil, J. M., Brockelman, F., Keeling, K., & Hall, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00916 · Cited by 51
Comparison of different methods for the extraction of cannabinoids from cannabis
De Vita, D., Madia, V. N., Tudino, V., Saccoliti, F., De Leo, A., Messore, A., Roscilli, P., Botto, A., Pindinello, I., Santilli, G., et al. (2020) · Natural Product Research · doi:10.1080/14786419.2019.1601194 · Cited by 50
Hybrid test for publication bias in meta-analysis
Lin, L. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220910172 · Cited by 51
Milosev, L. M., Psathakis, N., Szejko, N., Jakubovski, E., & Müller‐Vahl, K. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0050 · Cited by 52
Daily Cannabis Use is Associated With Lower CNS Inflammation in People With HIV
Watson, C. W., Campbell, L. M., Sun-Suslow, N., Hong, S., Umlauf, A., Ellis, R. J., Iudicello, J. E., Letendre, S. L., Marcotte, T. D., Heaton, R. K., et al. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617720001447 · Cited by 49
Cannabis and cannabinoids: pharmacology and therapeutic potential
Śmiarowska, M., Białecka, M., & Machoy-Mokrzyńska, A. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2022.0015 · Cited by 60
Cannabis in Palliative Care: A Systematic Review of Current Evidence
Doppen, M., Kung, S. M., Maijers, I., John, M., Dunphy, H., Townsley, H., Eathorne, A., Semprini, A. C., & Braithwaite, I. E. (2022) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2022.06.002 · Cited by 52
Ste‐Marie, P. A., Shir, Y., Rampakakis, E., Sampalis, J. S., Karellis, A., Cohen, M., Starr, M., Ware, M. A., & Fitzcharles, M. (2016) · Pain · doi:10.1097/j.pain.0000000000000706 · Cited by 49
Cannabis-Associated Asthma and Allergies
Chatkin, J. M., Zani-Silva, L., Ferreira, I., & Zamel, N. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8644-1 · Cited by 49
Bassi, M. S., Gilio, L., Maffei, P., Dolcetti, E., Bruno, A., Buttari, F., Centonze, D., & Iezzi, E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00424 · Cited by 51
A Review of Cannabis in Chronic Kidney Disease Symptom Management
Ho, C., Martinusen, D. J., & Lo, C. (2019) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358119828391 · Cited by 51
Merging the Pathophysiology and Pharmacotherapy of Tics
Augustine, F., & Singer, H. S. (2018) · Europe PMC (PubMed Central) · doi:10.7916/d8h14jtx · Cited by 49
Sihota, A., Smith, B. K., Ahmed, S., Bell, A., Blain, A., Clarke, H. A., Cooper, Z. D., Cyr, C., Daeninck, P. J., Deshpande, A., et al. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13871 · Cited by 50
Pharmacy Student Knowledge, Confidence and Attitudes Toward Medical Cannabis and Curricular Coverage
Caligiuri, F. J., Ulrich, E. E., & Welter, K. J. (2018) · American Journal of Pharmaceutical Education · doi:10.5688/ajpe6296 · Cited by 48
A Systematic Review of the Neurocognitive Effects of Cannabis Use in Older Adults
Scott, E. P., Brennan, E., & Benitez, A. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00285-9 · Cited by 48
Differences in Opinions About Marijuana Use and Prevalence of Use by State Legalization Status
Steigerwald, S., Cohen, B. E., Vali, M., Hasin, D. S., Cerdá, M., & Keyhani, S. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000593 · Cited by 48
Cannabinoids in the descending pain modulatory circuit: Role in inflammation
Bouchet, C. A., & Ingram, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107495 · Cited by 53
Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids
Sholler, D. J., Huestis, M. A., Amendolara, B., Vandrey, R. G., & Cooper, Z. D. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173059 · Cited by 50
Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model
Mitchell, V. A., Harley, J. C., Casey, S. L., Vaughan, A. C., Winters, B. L., & Vaughan, C. W. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108529 · Cited by 50
Cannabis for the treatment of ulcerative colitis
Kafil, T. S., Nguyen, T. M., MacDonald, J. K., & Chande, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012954.pub2 · Cited by 47
Assessing Health Care Providers' Knowledge of Medical Cannabis
Kruger, D. J., Mokbel, M. A., Clauw, D. J., & Boehnke, K. F. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0032 · Cited by 47
Metadata
- Authors
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J.
- Affiliations
- University Hospitals Bristol NHS Foundation Trust (GB)
- Kleijnen Systematic Reviews (United Kingdom) (GB)
- Department of Medical, Oral, and Biotechnological Sciences, University “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy5Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru7Health Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
- Radboud University Medical Center (NL)
- Institut für Epidemiologie und kongenitale Erkrankungen, Cepicon GmbH, Hamburg, Germany
- Maastricht University (NL)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-23
- Volume
- 313
- Issue
- 24
- Pages
- 2456
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120227293
- Semantic Scholar
- 029bce497e0633eb2a7895cfd3b315f9c462dd5f
- Cited by
- 2,169
- References
- 137
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 168 · 2023: 200 · 2022: 220 · 2021: 262 · 2020: 272 · 2019: 230 · 2018: 209 · 2017: 159 · 2016: 131 · 2015: 33
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- cannabinoids, medical cannabis, nausea and vomiting, chemotherapy-induced nausea, chronic pain, spasticity, multiple sclerosis, depression, anxiety, sleep disorders, psychosis, glaucoma, Tourette syndrome, adverse events, quality of life, activities of daily living, risk of bias, placebo comparison
- MeSH terms
- Anorexia, Mental Disorders, Cannabinoids, Tourette Syndrome, Glaucoma, Humans, Muscle Spasticity, Nausea, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
